Coronavirus vaccine candidate displays protective traits

July 20, 2020

Coronavirus vaccine candidate displays protective traits

Deborah Fuller's lab has worked nonstop for months to test vaccine platforms against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Jesse Erasmus, senior fellow in the lab, developed what they call an "amplified RNA vaccine." That means it both produces more protein, which leads to a better immune response, and it triggers the immune system to be ready to respond. 

"I hadn’t ever seen that before with any other candidate nucleic acid vaccine, so that got us very excited and we realized that we may be onto a rapid response vaccine to COVID-19," said Fuller, professor of microbiology at the University of Washington School of Medicine. 

The next step would be Phase 1 human clinical trials. See our related news release.


Terms of appropriate usage of file downloads

  • News reporters and news organizations may freely republish and distribute videos, still images and audio files produced by UW Medicine and the University of Washington School of Medicine.
  • Works must be attributed/credited appropriately (for example, “UW Medicine” – as denoted in the file) and must not be used for commercial purposes.
  • These visual and audio files may not be used to exploit or misrepresent UW Medicine or the University of Washington.
  • UW Medicine often licenses still images from Thinkstock but cannot grant republishing rights. You may not republish single image files credited to Thinkstock.
  • Logos of UW Medicine and University of Washington Health Sciences schools may not be republished without explicit permission. Contact us by phone or email: 206.543.3620 or